Robert Salk, DO
Obstetrics & Gynecology · Warwick, RINPI 1548280555
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.6% of the total across 182 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,508 and has fallen 97.9% since, to $31 in 2025.
Across 182 payments — averaging $23.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$705
- AbbVie$630
- Myovant Sciences Inc.$398
- Exeltis, USA Inc.$294
- Sumitomo Pharma America, Inc.$272
- Pfizer$260
- plus $2K from 25 others
What the payments were for
- Travel & lodging$3107%
- Food & beverage$3,87693%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 7 | $705 |
| AbbVie(2 entities) | 33 | $630 |
| Myovant Sciences Inc. | 21 | $398 |
| Exeltis, USA Inc. | 15 | $294 |
| Sumitomo Pharma America, Inc. | 15 | $272 |
| Pfizer | 12 | $260 |
| Therapeuticsmd, Inc. | 18 | $254 |
| Astellas Pharma US Inc | 8 | $253 |
| Amgen | 3 | $159 |
| Hologic Sales And Service, LLC | 3 | $106 |
| Mylan Pharmaceuticals Inc. | 4 | $75 |
| Daiichi Sankyo Inc. | 4 | $69 |
| Merck | 4 | $66 |
| Bayer | 4 | $65 |
| Lupin Inc. | 4 | $62 |
| Currax Pharmaceuticals LLC | 4 | $60 |
| Evofem Biosciences, Inc. | 3 | $52 |
| Johnson & Johnson | 2 | $52 |
| Coopersurgical, Inc. | 3 | $51 |
| Agile Therapeutics, Inc. | 2 | $36 |
| Smith+Nephew | 1 | $34 |
| Biohaven Pharmaceuticals, Inc. | 2 | $29 |
| Covidien LP | 1 | $28 |
| Avion Pharmaceuticals | 2 | $25 |
| Roche Diagnostics Corporation | 1 | $25 |
| Eisai Inc. | 1 | $24 |
| Mayne Pharma Commercial LLC | 1 | $24 |
| Medicem Inc. | 1 | $23 |
| Pacira Pharmaceuticals Incorporated | 1 | $23 |
| Novo Nordisk | 1 | $16 |
| Medtronic | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,186 in reported general payments places this provider in the 85th percentile of 139 obstetrics & gynecology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 41 | $20,410 |
| GemtesaVibegron | 23 | $14,368 |
| Estradiol | 104 | $4,891 |
| Estradiol (Once Weekly)Estradiol | 30 | $1,471 |
| Estradiol (Twice Weekly)Estradiol | 18 | $942 |
| Oxybutynin Chloride | 45 | $880 |
| ValacyclovirValacyclovir Hcl | 15 | $696 |
| Clobetasol Propionate | 22 | $581 |
| Nystatin | 19 | $257 |
| JunelNorethindrone Ac/Eth Estradiol | 17 | $219 |
| Medroxyprogesterone Acetate | 12 | $134 |
| Acyclovir | 14 | $75 |
| Fluconazole | 12 | $69 |
| Triamcinolone Acetonide | 14 | $66 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $253 | $20,41041 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $272 | $14,36823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 139 obstetrics & gynecology providers in Rhode Island.
Other obstetrics & gynecology in Warwick
- Mauro ColavitaWarwick$23K
- Bethany WortmanWarwick$2K
- Luce Auriane KassiWarwick$2K
- Jessica MooreWarwick$425
- Mary SimpsonWakefield$50K
- Warren HuberProvidence$50K
- Lisa BoyleProvidence$30K
- Renee EgerProvidence$24K
- Gary WhartonProvidence$22K
- Christine FoleyProvidence$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.